文献速递质量管理与危急值临床生化临床免疫

医学实验室结果一致化:成就与挑战

Result harmonization in medical laboratories: accomplishments and challenges.
PubMed 文献 · Clin Chem Lab Med · 2026-03-13

本文基于JCTLM 2025年双年成员与利益相关方研讨会的讨论,聚焦医学实验室结果一致化的期望与益处及实现过程中的挑战。文章指出,通过应用计量溯源性原则可实现终端IVD测量程序结果的一致化,但历史上存在多个标准化努力未达到所需一致化水平的案例,原因涉及被测量定义不清、IVD-MP选择性差异、二级有证参考物质互换性特征问题、CRM处理不一致及IVD制造商采纳实施不足等。结果不一致可导致混淆、治疗延迟、医疗决策错误和医疗成本增加。文章强调外部质量评估提供者在评估不同IVD-MP结果一致性及识别等价性变化方面的重要作用,并指出未来需要JCTLM、IFCC和IVD制造商等机构间的领导与合作。

要点

  • 计量溯源是实现IVD测量程序结果一致化的基础,但历史标准化努力存在失败案例。
  • 一致化失败原因涉及被测量定义、选择性、参考物质互换性、校准品制备及制造商实施等多环节。
  • 结果不一致可导致混淆、治疗延迟、决策错误和成本增加,EQA需使用互换性材料评估一致性。

核心结论

  • 通过计量溯源性原则可实现IVD测量程序结果的一致化,但多个历史标准化努力未达到所需一致化水平。

研究设计与样本

  • 本文为JCTLM 2025年双年成员与利益相关方研讨会的总结报告,聚焦医学实验室结果一致化的期望、益处与挑战。

主要发现

  • 历史标准化失败原因包括被测量定义不清、IVD-MP选择性差异、二级CRM互换性特征问题、CRM处理不一致及制造商采纳实施不足。
  • 结果不一致可导致混淆、治疗延迟、医疗决策错误和医疗成本增加。
  • 部分常用检测仍缺乏计量溯源性的原因是缺乏CRM、参考方法程序(RMP)和/或参考方法服务(RMS)。
  • EQA提供者需使用与临床样本互换的材料,才能评估不同IVD-MP结果的一致性及等价性变化。

关键数值与推荐

  • 一致化可通过应用计量溯源性原则实现,但需确保被测量定义清晰、IVD-MP选择性一致、CRM互换性良好且处理规范、制造商采纳实施到位。
  • EQA材料必须与临床样本互换,才能反映临床样本结果的一致化状态。

临床怎么用

  • 检验科应关注检测结果的计量溯源性,优先选择具有明确溯源链的IVD测量程序。
  • 利用EQA计划评估不同IVD-MP结果的一致性,并关注EQA材料的互换性。
  • 关注JCTLM、IFCC与IVD制造商的合作进展,以推动结果一致化的实现。

局限性

  • 本文为研讨会总结,未提供原始研究数据或系统评价。
  • 未具体说明各失败案例的详细数值或比例。
  • 未涉及具体法规框架的细节或实施时间表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Joint Committee for Traceability in Laboratory Medicine (JCTLM) supports worldwide equivalence and comparability of measurement results in laboratory medicine to improve health care and facilitate national and international trade in in vitro diagnostic (IVD) medical devices. The 2025 biennial members and stakeholders' workshop focused on the expectations and benefits of harmonized results among medical laboratories, as well as the challenges associated with achieving this goal. Harmonization of results from end-user IVD measurement procedures (IVD-MPs) can be achieved by applying the principles of metrological traceability; however, there are several historical examples of standardization efforts that did not achieve the required level of harmonization. The reasons for these failures can be found in various elements of the calibration hierarchy including: a) an unclear definition of the measurand, b) differences in selectivity of the IVD-MPs, c) issues with the commutability characteristics of secondary certified reference materials (CRM), d) inconsistencies in handling of CRMs to prepare calibrators, and e) lack of adoption and implementation by the IVD manufacturers. The lack of harmonized results can lead to confusion, treatment delays, errors in medical decisions, and increased healthcare costs. There are still assays in common use that lack metrological traceability because they lack CRMs, reference method procedures (RMPs), and/or reference method services (RMSs). Producing and maintaining reference measurement system components is complex and expensive. There are multiple regulatory frameworks and requirements that IVD manufacturers must meet worldwide. There is a vital role for External Quality Assessment (EQA) providers to assess the agreement status of results across different IVD-MPs and identify any changes in their equivalence. However, EQA materials must be commutable with clinical samples for each of the examined IVD-MDs for results to reflect the status of harmonization of clinical sample results. The future will need leadership and cooperation between bodies such as JCTLM, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and IVD manufacturers.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Badrick T, Beasley-Green A, Cobbaert CM, et al. Result harmonization in medical laboratories: accomplishments and challenges. Clin Chem Lab Med. 2026. PMID: 41832618. doi:10.1515/cclm-2026-0323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。